MSCs vs. iPSCs: Potential in therapeutic applications

• Main Authors: Thanaskody, Kalaiselvaan, Jusop, Amirah Syamimi, Tye, Gee Jun, Zaman, Wan Safwani Wan Kamarul, Dass, Sylvia Annabel, Nordin, Fazlina
• Format: Article
• Published: Frontiers Media Sa 2022
• Subjects: RM Therapeutics. Pharmacology
• Online Access: http://eprints.um.edu.my/46187/; https://doi.org/10.3389/fcell.2022.1005926
• Institution: Universiti Malaya

Over the past 2 decades, mesenchymal stem cells (MSCs) have attracted a lot of interest as a unique therapeutic approach for a variety of diseases. MSCs are capable of self-renewal and multilineage differentiation capacity, immunomodulatory, and anti-inflammatory properties allowing it to play a role in regenerative medicine. Furthermore, MSCs are low in tumorigenicity and immune privileged, which permits the use of allogeneic MSCs for therapies that eliminate the need to collect MSCs directly from patients. Induced pluripotent stem cells (iPSCs) can be generated from adult cells through gene reprogramming with ectopic expression of specific pluripotency factors. Advancement in iPS technology avoids the destruction of embryos to make pluripotent cells, making it free of ethical concerns. iPSCs can self-renew and develop into a plethora of specialized cells making it a useful resource for regenerative medicine as they may be created from any human source. MSCs have also been used to treat individuals infected with the SARS-CoV-2 virus. MSCs have undergone more clinical trials than iPSCs due to high tumorigenicity, which can trigger oncogenic transformation. In this review, we discussed the overview of mesenchymal stem cells and induced pluripotent stem cells. We briefly present therapeutic approaches and COVID-19-related diseases using MSCs and iPSCs.